Pakvis, Leon (2019) Current trends of hemagglutinin and M2 protein inhibition for the treatment of influenza using antivirals. Bachelor's Thesis, Biology.
|
Text
bBIO_2019_PakvisLR.pdf Download (339kB) | Preview |
|
![[img]](https://fse.studenttheses.ub.rug.nl/style/images/fileicons/text.png) |
Text
toestemming.pdf Restricted to Registered users only Download (183kB) |
Abstract
Influenza is an annually returning illness with a great physical and economic burden. Currently, the most commonly used medication for influenza is vaccination. However, every year, a new vaccine has to be created to combat a newly formed influenza strain as a result of antigenic drift and shift. Moreover, creating new vaccines to combat new influenza strains costs money and time. Another way of treating influenza is via the use of antivirals. Production of these drugs is faster and they are not strain-specific. Currently used antivirals focus on targeting neuraminidase and cap-dependent nuclease proteins of the exit and replication phase of influenza virus, respectively. This review investigates ongoing and future research in antivirals targeting hemagglutinin and matrix protein 2 of the entry phase of influenza. The most promising upcoming antivirals are hemagglutinin inhibiting drugs, such as Arbidol, Nitazoxanide, and Urumin. More research in matrix protein 2 inhibition is still necessary, with a low number of viable candidates and low barrier of drug-resistance being the main problems.
| Item Type: | Thesis (Bachelor's Thesis) |
|---|---|
| Supervisor name: | Huckriede, A.L.W. |
| Degree programme: | Biology |
| Thesis type: | Bachelor's Thesis |
| Language: | English |
| Date Deposited: | 19 Jun 2019 |
| Last Modified: | 19 Jun 2019 11:35 |
| URI: | https://fse.studenttheses.ub.rug.nl/id/eprint/19637 |
Actions (login required)
 |
View Item |